Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.


Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks.

Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5860-5. Epub 2007 Mar 26.


The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.

Clin Cancer Res. 2007 Mar 15;13(6):1911-25.


From Tpr-Met to Met, tumorigenesis and tubes.

Peschard P, Park M.

Oncogene. 2007 Feb 26;26(9):1276-85. Review.


Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.


A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA.

Cancer Cell. 2006 May;9(5):341-9.


Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.


Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules.

Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, White FM.

Mol Cell Proteomics. 2005 Sep;4(9):1240-50. Epub 2005 Jun 11.


Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.

Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, Henriksson R.

Acta Neuropathol. 2004 Aug;108(2):135-42. Epub 2004 May 18.


Met, metastasis, motility and more.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.

Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25. Review. No abstract available.


A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.


A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R.

Cancer Res. 2003 Sep 1;63(17):5462-9.


Genetics and new approaches to cancer therapy.

Cavenee WK.

Carcinogenesis. 2002 May;23(5):683-6. No abstract available.


Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.

Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ.

J Neurosurg. 2001 Sep;95(3):472-9.


Malignant glioma: genetics and biology of a grave matter.

Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA.

Genes Dev. 2001 Jun 1;15(11):1311-33. Review. No abstract available.


Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.

Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM, Laterra J.

Cancer Res. 2000 Aug 1;60(15):4277-83.


Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor.

Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ.

J Biol Chem. 1998 Jan 2;273(1):200-6.

Items per page

Supplemental Content

Write to the Help Desk